


Claims

1. Compounds having the general formula (I):



wherein

R¹ and R² are independently selected from the group comprising:

10 -H, -F, -Cl, -Br, -I, -NH₂, -OH, -SH, -CN, linear or branched, substituted or unsubstituted C₁–C₆ alkyl, linear or branched, substituted or unsubstituted C₂–C₆ alkenyl, linear or branched, substituted or unsubstituted C₂–C₆ alkinyl, substituted or unsubstituted C₃–C₈ cycloalkyl, linear or branched, substituted or unsubstituted C₁–C₆ alkoxy, linear or branched, substituted or unsubstituted C₁–C₆ haloalkyl or linear or branched, substituted or unsubstituted C₁–C₆ thioalkyl;

15 R³ is selected from substituted or unsubstituted C₃–C₈ cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclyl;

20 R⁴ is selected from -H or linear or branched C₁–C₆ alkyl;

R⁵ is selected from the group consisting of:

25 -H, substituted or unsubstituted, linear or branched C₁–C₆ alkyl, substituted or unsubstituted C₃–C₈ cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl,

-(CH₂)_m–R⁶

30 wherein m is selected to be an integer from 0 to 6 and

R⁶ is selected from -H, substituted or unsubstituted C₃–C₈ cycloalkyl, aryl substituted or unsubstituted, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclyl, if m is selected to be an integer from 1 to 6, at least one, preferably one to two hydrogen atoms bonded to the -(CH₂)_m carbon chain are optionally substituted by -F, -Cl, -Br, -I, -OH, -NH₂, linear or branched C₁–C₆ alkyl or linear or branched C₁–C₆ alkoxy,


or $-(CH_2)_n-N(R^7)_2$

wherein n is an integer from 1 to 6 and R^7 is selected from $-H$ or linear or branched C_1-C_6 alkyl; if n is selected to be an integer from 1 to 6, at least one, preferably one to two hydrogen atoms bonded to the $-(CH_2)_n$ carbon chain are optionally substituted by $-F$, $-Cl$, $-Br$, $-I$, $-OH$, $-NH_2$, linear or branched C_1-C_6 alkyl or linear or branched C_1-C_6 alkoxy

10 under the proviso, that if R_4 is $-H$, R_5 is different from $-H$;

or wherein

R^4 and R^5 together form a ring system represented by the formula (II)



15

wherein o and p are independently selected to be an integer from 1 to 3, Z is selected from CH or N, each R^8 and each R^9 represent independently from each other $-H$, linear or branched C_1-C_6 alkyl or

$-(CH_2)_u-OH$

20 wherein u is selected to be an integer from 0 to 6 and if u is selected to be an integer from 1 to 6, at least one, preferably one to two hydrogen atoms bonded to the $-(CH_2)_u$ carbon chain are optionally substituted by $-F$, $-Cl$, $-Br$, $-I$, $-OH$, $-NH_2$, linear or branched C_1-C_6 alkyl or linear or branched C_1-C_6 alkoxy,

25 R^{10} is selected from the group comprising:
30 $-H$, linear or branched, substituted or unsubstituted C_1-C_6 alkyl, linear or branched, substituted or unsubstituted C_2-C_6 alkenyl, linear or branched, substituted or unsubstituted C_2-C_6 alkinyl, substituted or unsubstituted C_3-C_8 cycloalkyl, linear or branched, substituted or unsubstituted C_1-C_6 alkoxy,

linear or branched, substituted or unsubstituted C₁–C₆ haloalkyl or linear or branched, substituted or unsubstituted C₁–C₆ thioalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocyclyl,

5 –C(O)–R¹¹ or –(CH₂)_q–R¹¹

wherein q is an integer from 0 to 6, and R₁₁ is selected from linear or branched, substituted or unsubstituted C₁–C₆ alkyl, linear or branched, substituted or unsubstituted C₂–C₆ alkenyl, linear or branched, substituted or unsubstituted C₂–C₆ alkinyl, substituted or unsubstituted C₃–C₈ cycloalkyl, linear or branched, substituted or unsubstituted C₁–C₆ alkoxy, linear or branched, substituted or unsubstituted C₁–C₆ haloalkyl or linear or branched, substituted or unsubstituted C₁–C₆ thioalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclyl,

10

15

and stereoisomeric forms, prodrugs and/or pharmaceutically acceptable salts thereof.

20 2. The compound according to claim 1, wherein R¹ is selected from –H, linear or branched C₁–C₆ alkyl or –NH₂, preferably from –H, linear or branched C₁–C₄ alkyl or –NH₂, and more preferably from –H, –CH₃ or –NH₂ and most preferably from –H.

25 3. The compound according to any one of claims 1 to 2, wherein R² is selected from –H, linear or branched C₁–C₆ alkyl or –NH₂, preferably from –H, linear or branched C₁–C₄ alkyl or –NH₂, and more preferably from –H or –CH₃, and most preferably from –H.

30 4. The compound according to any one of claims 1 to 3, wherein R³ is selected from the group consisting of: substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclyl, and preferably is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.

35

5. The compound according to any one of claims 1 to 4, wherein R⁴ is selected from –H or linear or branched C₁–C₄ alkyl, preferably from –H or –CH₃, and is most preferably –H,
R⁵ is selected from

linear or branched C₁–C₆ alkyl, preferably from linear or branched C₁–C₄ alkyl, more preferably from –C₂H₅ or –C₃H₇,

–(CH₂)_m–R⁶

5 wherein m is selected to be an integer from 0 to 4, preferably from 0 to 2, and wherein R⁶ is selected from the group comprising: –H, substituted or unsubstituted aryl, preferably substituted or unsubstituted phenyl, 2-thiophenyl, 3-indolyl,

10 heteroaryl, selected from the group comprising: pyridinyl, pyrrolyl, furanyl, thiophenyl, benzo[b]thiophenyl, benzofuranyl or indolyl, preferably 4-pyridinyl, 2-furanyl,

or –(CH₂)_n–N(R⁷)₂,

15 wherein n is selected to be an integer from 1 to 4, preferably from 1 to 2 and each R⁷ is independently selected from –H or linear or branched C₁–C₄ alkyl, and preferably is –H or –CH₃.

15

6. The compound according to claim 5, wherein R³ is selected from the group consisting of:

substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, preferably aryl or bicyclic heteroaryl, more preferably phenyl, naphthyl, benzofuranyl or indolyl, and is most preferably phenyl.

20

7. The compound according to claim 6, wherein R³ and R⁶ are selected to be phenyl, each independently of the other partially or fully substituted with members selected from the group consisting of:

25

–F, –Cl, –Br, –I, –OH, linear or branched C₁–C₄ alkoxy, linear or branched C₁–C₄ alkyl, linear or branched C₁–C₄ haloalkyl, –CN, –C(O)–NH–(CH₂)_s–N(R¹²)₂ group,

30

wherein s is an integer from 0 to 4, preferably an integer from 0 to 3, and is most preferably 2 and wherein each R¹² represents independently from each other –H or linear or branched C₁–C₄ alkyl, and preferably is –H or –CH₃ or

–C(O)–R¹³ group

35

wherein R¹³ is selected to be –N(R¹²)₂


wherein each R¹² represents independently from each other –H or linear or branched C₁–C₄ alkyl, and preferably is –H.

8. The compound according to claim 7, wherein R³ and R⁶ are independently of the other substituted with members selected from the group comprising: –F, –Cl, –CN, –OH, –OCH₃, –CF₃, –CH₃ or –C(O)NH₂,

and wherein each phenyl is preferably mono-, di- or trisubstituted, more preferably mono- or disubstituted.

9. The compound according to any one of claims 1 to 8, wherein R⁵ is
 5 selected to be $-(CH_2)_n-N(R^7)_2$, wherein n is selected to be an integer from 1 to 4, preferably from 1 to 3, and is most preferably 2, and wherein each R⁷ is independently selected from -H, linear or branched C₁-C₄ alkyl, and preferably is -CH₃ and R₃ is selected from aryl or heteroaryl, preferably from aryl, and is most preferably naphthyl.

10. The compound according to claim 1 to 5, wherein R⁴ and R⁵ form a ring system represented by the formula (II)



15 wherein o and p are independently selected to be 1 or 2, preferably o is selected to be 1 or 2 and p is selected to be 2, and most preferably o and p are both selected to be 2,
 each R⁸ and each R⁹ is independently selected from the group comprising:
 20 $-(CH_2)_u-OH$, wherein u is an integer from 0 to 4, preferably from 0 to 2,
 -H or linear or branched C₁-C₄ alkyl, preferably -H or -CH₃,
 Z is N or CH,
 R¹⁰ is selected from the consisting of:
 25 -H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl,
 $-(CH_2)_q-R^{11}$ or $-C(O)-R^{11}$
 wherein q is selected to be an integer from 0 to 6,
 R¹¹ is selected to be a heteroarylor heterocyclyl, preferably a 5
 membered monocyclic heteroaryl or a 5 membered monocyclic
 30 heterocyclyl, and is most preferably thiophenyl, furanyl, pyrrolyl or
 pyrrolidinyl.

11. The compound according to claim 10, wherein Z is selected to be CH.

12. The compound according to claim 11, wherein o is selected to be 1 and p is selected to be 2, R⁸ is -H, each R⁹ represents independently from each other -H or -CH₂-OH, R³ is a heteroaryl, preferably a bicyclic heteroaryl, and is most preferably benzofuranyl and R¹⁰ is -H.

5

13. The compound according to claim 11, wherein o and p are selected to be 2, each R⁸ and each R⁹ are selected to be -H, R³ is selected to be substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, and

10 R¹⁰ is selected to be substituted or unsubstituted aryl, preferably substituted or unsubstituted phenyl.

14. The compound according to claim 13, wherein R³ is selected from the group comprising:

15 furanyl, thiophenyl, pyrrolidinyl, preferably 3-furanyl or 3-thiophenyl, benzo[b]thiophenyl, benzofuranyl, indolyl, preferably 3-benzo[b]thiophenyl, naphthyl or phenyl, each of these moieties being substituted or unsubstituted with members of the group consisting of:

20 -F, -Cl, -Br, -I, preferably -F or -Cl, linear or branched C₁-C₄ alkoxy, preferably -OCH₃, linear or branched C₁-C₄ thioalkyl, preferably -SCH₃, -(CH₂)_r-N(R¹²)₂,

25 wherein r is an integer from 0 to 4, preferably from 0 to 2, and is most preferably 0 and wherein each R¹² represents independently from each other -H or linear or branched C₁-C₄ alkyl, preferably -CH₃, or

30 -C(O)-R¹³ wherein R¹³ is selected to be linear or branched C₁-C₄ alkyl, preferably -CH₃.

15. The compound according to claim 10, wherein Z is selected to be N and wherein o and p are independently selected to be an integer from 1 to 3, preferably o and p are selected to be 2, each R⁸ and each R⁹ are independently selected from -H or -CH₃,

35 R³ is selected from substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, and

R¹⁰ is selected from the group comprising: substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl,

or $-\text{C}(\text{O})-\text{R}^{11}$ or $-(\text{CH}_2)_q-\text{R}^{11}$

wherein R^{11} is selected from heteroaryl or heterocycl and q is an integer from 0 to 4, preferably from 0 to 2.

5 16. The compound according to claim 15, wherein each R^8 and one R^9 represent $-\text{H}$, and one R^9 represents $-\text{CH}_3$.

10 17. The compound according to claim 16, wherein R^{10} is phenyl, optionally fully or partially substituted, preferably monosubstituted, with linear or branched C_1-C_4 alkyl, preferably $-\text{CH}_3$, and wherein R^3 is selected from the group comprising: substituted or unsubstituted naphthyl, bicyclic heteroraryl, preferably benzo[b]thiophenyl, or phenyl, , preferably mono- or disubstituted, with members of the group consisting of: linear or branched C_1-C_4 alkyl, preferably $-\text{CH}_3$, linear or branched C_1-C_4 thioalkyl, preferably $-\text{S}-\text{CH}_3$ or $-\text{CO}(\text{NR}^{12})_2$, wherein each R^{12} represents independently from each other $-\text{H}$ or linear or branched C_1-C_4 alkyl, preferably $-\text{H}$

15 18. The compound according to claim 15, wherein each R^8 and R^9 is $-\text{H}$.

20 19. The compound according to claim 18, wherein R^{10} is selected from the group consisting of: Phenyl, pyridinyl, pyrimidinyl, pyrazinyl, benzo[b]thiophenyl, benzofuranyl , indolyl, $-\text{C}(\text{O})-\text{R}^{11}$ wherein R^{11} is a monocyclic heteroaryl, preferably furanyl, or $-(\text{CH}_2)_q-\text{R}^{11}$ wherein q is selected to be 2 and R^{11} is a monocyclic heterocycl, preferably pyrrolidinyl.

25 30 20. The compound according to claim 19, wherein R^{10} is selected from the group comprising: pyridinyl, pyrazinyl, indolyl or phenyl.

30 35 21. The compound according to claim 21, wherein R^{10} is pyridinyl, preferably 2-pyridinyl or 4-pyridinyl, more preferably 4-pyridinyl or phenyl, which is optionally fully or partially substituted, preferably mono- or disubstituted, with members of the group consisting of: $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, or $-\text{I}$, preferably $-\text{F}$ or $-\text{Cl}$, linear or branched C_1-C_4 alkoxy, preferably $-\text{OCH}_3$, linear or branched C_1-C_4 alkyl, preferably $-\text{CH}_3$,

linear or branched C₁–C₄ haloalkyl, preferably –CF₃
–CN or –(CO)–R¹³, wherein R¹³ represents linear or branched C₁–C₄ alkyl,
preferably –CH₃.

5 22. The compound according to any one of claims 18 to 21, wherein R³ is
selected from the group consisting of: phenyl, naphthyl, pyrrolyl,
thiophenyl, furanyl, preferably 2-thiophenyl, 3-thiophenyl, 2-furanyl or 3-
furanyl; pyridinyl, preferably 3-pyridinyl; benzo[b]thiophenyl,
benzofuranyl, indolyl, preferably benzo[b]thiophenyl or benzofuranyl and
10 wherein all of these group members are optionally partially or fully
substituted.

15 23. The compound according to claim 22, wherein
naphthyl is optionally partially or fully substituted with C₁–C₄ alkoxy,
thiophenyl is optionally partially or fully substituted with
–(CO)–R¹³
20 wherein R¹³ represents linear or branched C₁–C₄ alkyl, preferably –CH₃
and wherein naphthyl or thiophenyl are preferably monosubstituted.

25 24. The compound according to claim 23, wherein R³ is phenyl, which is
optionally partially or fully substituted with members of the group
comprising:
–F, –Cl, –Br, –I, –CN, linear or branched C₁–C₄ alkoxy, –OPh, linear or
30 branched C₁–C₄ alkyl, phenyl, linear or branched C₁–C₄ haloalkyl, linear or
branched C₁–C₄ thioalkyl,
–(CH₂)–X,
wherein X is selected to be –OH or –(NR¹²)₂
35 wherein r is an integer from 0 to 2, preferably r is 0 or 1 and
each R¹² represents independently from each other –H or
linear or branched C₁–C₄ alkyl, preferably –H or –CH₃,
–(CO)–R¹³
wherein R¹³ represents linear or branched C₁–C₄ alkyl, preferably
40 –CH₃ or –(NR¹²)₂, wherein each R¹² represents independently from
each other –H or linear or branched C₁–C₄ alkyl, preferably –H,
–NH–(CO)–R¹⁴,
wherein R¹⁴ is selected from –H or linear or branched C₁–C₄ alkyl,
preferably –CH₃,

or

$-\text{C}(\text{O})-\text{NH}-(\text{CH}_2)_s-\text{OH}$, wherein s is selected to be an integer from 0 to 4, and is preferably 2.

5 25. The compound according to claim 24, wherein the R^3 -phenyl group is preferably substituted with members selected from the group comprising:
-F, -Cl, -Br, preferably -F or -Cl,
-O-CH₃, -O-C₂H₅, -SCH₃, -CH₃, -CH(CH₃)₂, -C(CH₃)₃, -CH₂OH,
-N(CH₃)₂, -CF₃ or -C(O)NH₂

10 and wherein the phenyl is preferably mono-, di- or trisubstituted, more preferably mono- or disubstituted.

26. The compound according to any one of claims 18-25, wherein R^1 and R^2 are -H.

15 27. The compound according to any one of the preceding claims, wherein the compound is selected from the group of compounds consisting of:
(Compound 1) 4-(3,4-Dimethoxy-phenyl)-6'-naphthalen-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;
20 (Compound 2) 6'-(3-Chloro-phenyl)-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;
(Compound 3) 6'-(4-Isopropyl-phenyl)-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;
(Compound 4) 3-(4-Pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-phenol;
25 (Compound 5) 4-(3,4-Dimethoxy-phenyl)-6'-(4-isopropyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;
(Compound 6) {4-[4-(3,4-Dimethoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-methanol;
30 (Compound 7) [6-(3-Fluoro-phenyl)-pyrazin-2-yl]-{(3,4,5-trimethoxy-phenyl)-amine};
(Compound 8) 6'-(3-Fluoro-phenyl)-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;
35 (Compound 9) (6-Naphthalen-2-yl-pyrazin-2-yl)-(2-pyridin-4-yl-ethyl)-amine;
(Compound 10) 6'-Naphthalen-2-yl-4-pyridin-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;
(Compound 11) 4-[6-(3-Chloro-4-fluoro-phenylamino)-pyrazin-2-yl]-phenol;

(Compound 12) 6'-(4-Methoxy-phenyl)-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 13) N,N,N'-Trimethyl-N'-(6-naphthalen-2-yl-pyrazin-2-yl)-ethane-1,2-diamine;

5 (Compound 14) 6'-(4-Chloro-phenyl)-4-pyridin-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 15) 4-(4-Pyridin-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-benzamide;

10 (Compound 16) Dimethyl-[3-(4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-phenyl]-amine;

(Compound 17) 6'-Naphthalen-2-yl-4-(2-pyrrolidin-1-yl-ethyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 18) [6-(4-Methoxy-phenyl)-pyrazin-2-yl]-(2-pyridin-3-yl-ethyl)-amine;

15 (Compound 19) 6'-(2,4-Difluoro-phenyl)-4-pyridin-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 20) 4-[4-(3,4-Dimethoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-benzamide;

(Compound 21) 4-(4-Pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-benzamide;

20 (Compound 22) 3-[6-(3-Chloro-4-cyano-phenylamino)-pyrazin-2-yl]-N-(2-dimethylamino-ethyl)-benzamide;

(Compound 23) (6-Benzofuran-2-yl-pyrazin-2-yl)-furan-2-ylmethyl-amine;

25 (Compound 24) [1-(6-Benzofuran-2-yl-pyrazin-2-yl)-pyrrolidin-2-yl]-methanol;

(Compound 25) 4-(6-Propylamino-pyrazin-2-yl)-benzamide;

(Compound 26) [6-(4-Chloro-phenyl)-pyrazin-2-yl]-furan-2-ylmethyl-amine;

30 (Compound 27) Benzyl-[6-(4-chloro-phenyl)-pyrazin-2-yl]-amine;

(Compound 28) 4-(6-Benzylamino-pyrazin-2-yl)-benzamide;

(Compound 29) 4-[6-(3-Trifluoromethyl-phenylamino)-pyrazin-2-yl]-phenol;

(Compound 30) 4-{6-[(Thiophen-2-ylmethyl)-amino]-pyrazin-2-yl}-phenol;

35 (Compound 31) 4-Pyridin-2-yl-6'-thiophen-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 32) 4-Pyridin-4-yl-6'-(3-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 33) 6'-(3-Chloro-4-fluoro-phenyl)-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

5 (Compound 34) 4-[4-(Furan-2-carbonyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-benzamide;

(Compound 35) 4-{6-[2-(1H-Indol-3-yl)-ethylamino]-pyrazin-2-yl}-benzamide;

(Compound 36) N-{3-[4-(1H-Indol-4-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-acetamide;

10 (Compound 37) 4-(1H-Indol-4-yl)-6'-(3,4,5-trimethoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 38) 4-(1H-Indol-4-yl)-6'-(4-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

15 (Compound 39) N-(2-Hydroxy-ethyl)-3-(4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-benzamide;

(Compound 40) 4-(6-Ethylamino-pyrazin-2-yl)-benzamide;

(Compound 41) 6'-(2,4-Difluoro-phenyl)-4-(3,4-dimethoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

20 (Compound 42) 2-[6'-(4-Chloro-phenyl)-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl]-benzonitrile;

(Compound 43) 4-(3,4-Dimethoxy-phenyl)-6'-naphthalen-1-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 44) 4-(3,4-Dimethoxy-phenyl)-6'-thiophen-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

25 (Compound 45) 4-(3,4-Dimethoxy-phenyl)-6'-(4-ethoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 46) 6'-(2,4-Difluoro-phenyl)-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 47) 6'-(4-Chloro-phenyl)-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

30 (Compound 48) [6-(2,4-Difluoro-phenyl)-pyrazin-2-yl]-furan-2-ylmethyl-amine;

(Compound 49) 6'-Phenyl-4-pyridin-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

35 (Compound 50) 6'-(3,4-Dimethyl-phenyl)-4-pyridin-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 51) [6-(3,4-Dimethyl-phenyl)-pyrazin-2-yl]-furan-2-ylmethyl-amine;

(Compound 52) [3-(4-Pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-phenyl]-methanol;

5 (Compound 53) 6'-(3-Chloro-phenyl)-4-pyridin-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 54) 4-Pyridin-4-yl-6'-pyridin-3-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

10 (Compound 55) 6'-(5-Isopropyl-2-methoxy-phenyl)-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 56) 6'-(3-Fluoro-phenyl)-4-pyridin-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 57) 4-(4-Pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-phenol;

15 (Compound 58) Furan-2-yl-[6'-(3-hydroxymethyl-phenyl)-2,3,5,6-tetrahydro-1,2']bipyrazinyl-4-yl]-methanone;

(Compound 59) [6'-(4-Aminomethyl-phenyl)-2,3,5,6-tetrahydro-1,2']bipyrazinyl-4-yl]-furan-2-yl-methanone;

(Compound 60) 4-[4-(3,4-Dimethoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-benzylamine;

20 (Compound 61) {4-[4-(1H-Indol-4-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-methanol;

(Compound 62) 2-[6'-(3-Chloro-4-fluoro-phenyl)-2,3,5,6-tetrahydro-1,2']bipyrazinyl-4-yl]-benzonitrile;

25 (Compound 63) {3-[4-(2-Pyrrolidin-1-yl-ethyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-methanol;

(Compound 64) 4-(1H-Indol-4-yl)-6'-pyridin-3-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 65) 1-[5-(4-Pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-thiophen-2-yl]-ethanone;

30 (Compound 66) 6'-(4-Methylsulfanyl-phenyl)-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 67) 6'-Phenyl-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

35 (Compound 68) 4-(4-Phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-benzamide;

(Compound 69) 6'-Benzo[b]thiophen-2-yl-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 70) 2-(4-Pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-benzamide;

(Compound 71) 3-(4-Pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-benzamide;

5 (Compound 72) 6'-Naphthalen-2-yl-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 73) 6'-Naphthalen-2-yl-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-3'-ylamine;

10 (Compound 74) 4-(3'-Amino-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-benzamide;

(Compound 75) 6'- (4-Methylsulfanyl-phenyl)-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-3'-ylamine;

(Compound 76) 6'- (4-Fluoro-phenyl)-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

15 (Compound 77) 6'- (3,4-Dimethoxy-phenyl)-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 78) 6'- (3-Methoxy-phenyl)-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 79) 4-Pyridin-4-yl-6'-thiophen-3-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

20 (Compound 80) 4-(3-Chloro-phenyl)-6'-thiophen-3-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 81) 4-(3-Chloro-phenyl)-6'-naphthalen-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

25 (Compound 82) 4-(3-Chloro-phenyl)-6'-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 83) {4-[4-(3-Chloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-methanol;

(Compound 84) 4-(3-Chloro-phenyl)-6'-furan-3-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

30 (Compound 85) 4-(2-Methoxy-phenyl)-6'-thiophen-3-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 86) 4-(2-Methoxy-phenyl)-6'-naphthalen-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

35 (Compound 87) 4-(2-Methoxy-phenyl)-6'-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 88) 6'- (4-tert-Butyl-phenyl)-4-(2-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 89) 4-[4-(3-Chloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-benzamide;

(Compound 90) 6'-Furan-3-yl-4-(2-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

5 (Compound 91) 6'-(5-Chloro-2-methoxy-phenyl)-4-(2-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 92) 6'-(4-Ethoxy-phenyl)-4-(2-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 93) 6'-Naphthalen-2-yl-4-phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

10 (Compound 94) 4-Phenyl-6'-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 95) 6'-(4-tert-Butyl-phenyl)-4-phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

15 (Compound 96) 6'-(2-Fluoro-biphenyl-4-yl)-4-phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 97) 4-(3-Chloro-phenyl)-6'-phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 98) 4-(3-Chloro-phenyl)-6'-(3-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

20 (Compound 99) 4-(3-Chloro-phenyl)-6'-(4-fluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 100) 4-(3-Chloro-phenyl)-6'-(3,4-dimethoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

25 (Compound 101) 1-{3-[4-(3-Chloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-ethanone;

(Compound 102) 4-(3-Chloro-phenyl)-6'-(4-methylsulfanyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 103) 1-{4-[4-(3-Chloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-ethanone;

30 (Compound 104) 4-[4-(2-Methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-benzamide;

(Compound 105) 4-(2-Methoxy-phenyl)-6'-(3-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

35 (Compound 106) 6'-(4-Fluoro-phenyl)-4-(2-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 107) 6'-(3,4-Dimethoxy-phenyl)-4-(2-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 108) 4-(2-Methoxy-phenyl)-6'-(4-methylsulfanyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 109) 4,6'-Diphenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 110) 6'-(3-Methoxy-phenyl)-4-phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

5 (Compound 111) 6'-(4-Fluoro-phenyl)-4-phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 112) 1-[3-(4-Phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-phenyl]-ethanone;

10 (Compound 113) 4-(2-Fluoro-phenyl)-6'-(3-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 114) 4-(2-Fluoro-phenyl)-6'-(4-fluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 115) 1-[3-[4-(2-Fluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl]-ethanone;

15 (Compound 116) 4-(2-Fluoro-phenyl)-6'-(4-methylsulfanyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 117) [4-(4-Phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-phenyl]-methanol;

20 (Compound 118) 6'-Furan-3-yl-4-phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 119) 6'-(5-Chloro-2-methoxy-phenyl)-4-phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 120) 6'-(4-Methylsulfanyl-phenyl)-4-phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

25 (Compound 121) 6'-(4-Ethoxy-phenyl)-4-phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 122) 4-(2-Fluoro-phenyl)-6'-thiophen-3-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

30 (Compound 123) 4-(2-Fluoro-phenyl)-6'-naphthalen-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 124) 4-(2-Fluoro-phenyl)-6'-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 125) {4-[4-(2-Fluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-methanol;

35 (Compound 126) 4-(2-Fluoro-phenyl)-6'-furan-3-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 127) 6'-(4-Ethoxy-phenyl)-4-(2-fluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 128) 6'-(2-Fluoro-biphenyl-4-yl)-4-(2-fluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

5 (Compound 129) 4-(3-Chloro-phenyl)-6'-(4-ethoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 130) 1-{4-[4-(2-Fluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-ethanone;

10 (Compound 131) 4-(4-Pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-benzonitrile;

(Compound 132) 1-[3-(4-Pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-phenyl]-ethanone;

(Compound 133) 1-[4-(4-Pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-phenyl]-ethanone;

15 (Compound 134) 4-(3,4-Dimethoxy-phenyl)-6'-(3-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 135) 6'-Phenyl-4-p-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 136) 6'-(4-Fluoro-phenyl)-4-p-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

20 (Compound 137) 6'-(4-Methylsulfanyl-phenyl)-4-p-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 138) 4,6'-Bis-(4-fluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 139) 6'-(3,4-Dimethoxy-phenyl)-4-(4-fluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

25 (Compound 140) 4-(4-Fluoro-phenyl)-6'-(4-methylsulfanyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 141) 1-{2-[4-(2,4-Difluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-ethanone;

30 (Compound 142) 4-(2,4-Difluoro-phenyl)-6'-p-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 143) 4-(2,4-Difluoro-phenyl)-6'-naphthalen-1-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

35 (Compound 144) 4-(2,4-Difluoro-phenyl)-6'-(2,5-dimethoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 145) 6'-(3-Chloro-4-fluoro-phenyl)-4-(2,4-difluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 146) 1-{2-[4-(4-Acetyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-ethanone;

(Compound 147) 1-[4-(6'-m-Tolyl-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-phenyl]-ethanone;

5 (Compound 148) 1-[4-(6'-p-Tolyl-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-phenyl]-ethanone;

(Compound 149) 1-[4-(6'-Naphthalen-1-yl-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-phenyl]-ethanone;

10 (Compound 150) 1-{4-[6'-(2,3-Dimethyl-phenyl)-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl]-phenyl}-ethanone;

(Compound 151) 1-{4-[6'-(3-Chloro-4-fluoro-phenyl)-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl]-phenyl}-ethanone;

(Compound 152) 1-[4-(6'-Benzo[b]thiophen-3-yl-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-phenyl]-ethanone;

15 (Compound 153) 1-{2-[4-(3-Trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-ethanone;

(Compound 154) 6'-m-Tolyl-4-(3-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 155) 6'-p-Tolyl-4-(3-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

20 (Compound 156) 6'-(2,3-Dimethyl-phenyl)-4-(3-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 157) 6'-(3-Chloro-4-fluoro-phenyl)-4-(3-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

25 (Compound 158) 6'-Benzo[b]thiophen-3-yl-4-(3-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 159) 1-{4-[6'-(4-Methylsulfanyl-phenyl)-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl]-phenyl}-ethanone;

(Compound 160) 6'-Benzo[b]thiophen-2-yl-4-(3-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

30 (Compound 161) 6'-(3,4-Dimethoxy-phenyl)-4-(3-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 162) 1-{3-[4-(3-Trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-ethanone;

35 (Compound 163) 6'-(4-Phenoxy-phenyl)-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 164) 6'-(3,5-Bis-trifluoromethyl-phenyl)-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 165) 6'-(3,5-Dimethyl-phenyl)-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 166) 6'-(2-Methylsulfanyl-phenyl)-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

5 (Compound 167) 3-(4-Pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-benzonitrile;

(Compound 168) 4-(3,4-Dimethoxy-phenyl)-6'-(4-phenoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

10 (Compound 169) 4-(3,4-Dimethoxy-phenyl)-6'-(6-methoxy-naphthalen-2-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 170) 4-(3,4-Dimethoxy-phenyl)-6'-(3,5-dimethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

15 (Compound 171) 4-(3,4-Dimethoxy-phenyl)-6'-(2,3-dimethoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 172) 4-(3,4-Dimethoxy-phenyl)-6'-(4-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 173) 3-[4-(3,4-Dimethoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-benzonitrile;

20 (Compound 174) 4-(3,4-Dimethoxy-phenyl)-6'-(2-phenoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 175) 6'-(2-Ethoxy-phenyl)-4-p-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 176) Dimethyl-[4-(4-p-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-phenyl]-amine;

25 (Compound 177) 6'-(3,5-Dimethyl-phenyl)-4-p-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 178) 4-p-Tolyl-6'-(4-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 179) 6'-(3,5-Dimethyl-phenyl)-4-(4-fluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

30 (Compound 180) 4-(4-Fluoro-phenyl)-6'-(4-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 181) 4-(4-Fluoro-phenyl)-6'-(3-fluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

35 (Compound 182) {4-[4-(3-Chloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-dimethyl-amine;

(Compound 183) 4-(3-Chloro-phenyl)-6'-(2,3-dimethoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 184) 4-(3-Chloro-phenyl)-6'-(4-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 185) 4-(3-Chloro-phenyl)-6'-(2-phenoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

5 (Compound 186) {4-[4-(2-Methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-dimethyl-amine;

(Compound 187) 6'-(6-Methoxy-naphthalen-2-yl)-4-(2-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

10 (Compound 188) 4-(2-Methoxy-phenyl)-6'-(4-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 189) 6'-(4-Phenoxy-phenyl)-4-phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 190) Dimethyl-[4-(4-phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-phenyl]-amine;

15 (Compound 191) 6'-(3,5-Bis-trifluoromethyl-phenyl)-4-phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 192) 6'-(3,5-Dimethyl-phenyl)-4-phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 193) 4-Phenyl-6'-(4-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

20 (Compound 194) 6'-(3-Fluoro-phenyl)-4-phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 195) {4-[4-(2-Fluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-dimethyl-amine;

25 (Compound 196) 6'-(3,5-Bis-trifluoromethyl-phenyl)-4-(2-fluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 197) 4-(2-Fluoro-phenyl)-6'-(4-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 198) 4-(2-Fluoro-phenyl)-6'-(3-fluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

30 (Compound 199) 4-(2,4-Difluoro-phenyl)-6'-naphthalen-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 200) {4-[4-(2,4-Difluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-methanol;

35 (Compound 201) 4-(2,4-Difluoro-phenyl)-6'-furan-3-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 202) {2-[4-(2,4-Difluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-methanol;

(Compound 203) 4-(2,4-Difluoro-phenyl)-6'-(4-ethoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 204) 1-{4-[6'-(4-tert-Butyl-phenyl)-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl]-phenyl}-ethanone;

5 (Compound 205) 1-[4-(6-Furan-3-yl-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-phenyl]-ethanone;

(Compound 206) 1-{4-[6'-(3-Fluoro-4-methoxy-phenyl)-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl]-phenyl}-ethanone;

10 (Compound 207) 1-{4-[6'-(4-Ethoxy-phenyl)-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl]-phenyl}-ethanone;

(Compound 208) {4-[4-(2,4-Difluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-dimethyl-amine;

(Compound 209) 4-(2,4-Difluoro-phenyl)-6'-(3,5-dimethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

15 (Compound 210) 4-(2,4-Difluoro-phenyl)-6'-(4-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 211) 4-(2,4-Difluoro-phenyl)-6'-(3-fluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 212) 1-{4-[6'-(2-Ethoxy-phenyl)-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl]-phenyl}-ethanone;

20 (Compound 213) 1-{4-[6'-(6-Methoxy-naphthalen-2-yl)-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl]-phenyl}-ethanone;

(Compound 214) 1-{4-[6'-(3-Fluoro-phenyl)-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl]-phenyl}-ethanone;

25 (Compound 215) 1-{4-[6'-(2-Phenoxy-phenyl)-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl]-phenyl}-ethanone;

(Compound 216) Dimethyl-{4-[4-(3-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-amine;

(Compound 217) 6'-(2-Phenoxy-phenyl)-4-(3-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

30 (Compound 218) 1-[2-(4-Pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-phenyl]-ethanone;

(Compound 219) 4-Pyridin-4-yl-6'-m-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

35 (Compound 220) 4-Pyridin-4-yl-6'-p-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 221) 6'-Naphthalen-1-yl-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 222) 6'-Benzo[b]thiophen-3-yl-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 223) 4-(3,4-Dimethoxy-phenyl)-6'-m-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

5 (Compound 224) 4-(3,4-Dimethoxy-phenyl)-6'-p-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 225) 4-(3,4-Dimethoxy-phenyl)-6'-(2,5-dimethoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

10 (Compound 226) 4-(3,4-Dimethoxy-phenyl)-6'-(2,3-dimethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 227) 6'-Benzo[b]thiophen-3-yl-4-(3,4-dimethoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 228) 6'-m-Tolyl-4-p-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

15 (Compound 229) 4,6'-Di-p-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 230) 6'-Naphthalen-1-yl-4-p-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 231) 6'-Benzo[b]thiophen-3-yl-4-p-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

20 (Compound 232) 4-(4-Fluoro-phenyl)-6'-m-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 233) 4-(4-Fluoro-phenyl)-6'-p-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 234) 6'-(2,5-Dimethoxy-phenyl)-4-(4-fluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

25 (Compound 235) 6'-Benzo[b]thiophen-3-yl-4-(4-fluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 236) 1-{2-[4-(3-Chloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-ethanone;

30 (Compound 237) 4-(3-Chloro-phenyl)-6'-p-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 238) 6'-(3-Chloro-4-fluoro-phenyl)-4-(3-chloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 239) 6'-Benzo[b]thiophen-3-yl-4-(3-chloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

35 (Compound 240) 1-{2-[4-(2-Methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-ethanone;

(Compound 241) 4-(2-Methoxy-phenyl)-6'-p-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 242) 6'-(3-Chloro-4-fluoro-phenyl)-4-(2-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

5 (Compound 243) 6'-Benzo[b]thiophen-3-yl-4-(2-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 244) 4-Phenyl-6'-m-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

10 (Compound 245) 4-Phenyl-6'-p-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 246) 6'-Naphthalen-1-yl-4-phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 247) 6'-Benzo[b]thiophen-3-yl-4-phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

15 (Compound 248) 4-(2-Fluoro-phenyl)-6'-p-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 249) 4-(2-Fluoro-phenyl)-6'-naphthalen-1-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 250) 6'-(2,3-Dimethyl-phenyl)-4-(2-fluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

20 (Compound 251) 6'-Benzo[b]thiophen-3-yl-4-(2-fluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 252) 6'-Naphthalen-2-yl-4-(3-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 253) 6'-(4-tert-Butyl-phenyl)-4-(3-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

25 (Compound 254) {4-[4-(3-Trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-methanol;

(Compound 255) 6'-Furan-3-yl-4-(3-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

30 (Compound 256) 4-Pyridin-4-yl-6'-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 257) 6'-(4-tert-Butyl-phenyl)-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

35 (Compound 258) [4-(4-Pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-phenyl]-methanol;

(Compound 259) 6'-(5-Chloro-2-methoxy-phenyl)-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 260) 6'-(4-Ethoxy-phenyl)-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 261) 4-(3,4-Dimethoxy-phenyl)-6'-thiophen-3-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

5 (Compound 262) 4-(3,4-Dimethoxy-phenyl)-6'-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 263) 6'-(4-tert-Butyl-phenyl)-4-(3,4-dimethoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

10 (Compound 264) {2-[4-(3,4-Dimethoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-methanol;

(Compound 265) 6'-(3-Fluoro-4-methoxy-phenyl)-4-p-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 266) 6'-(4-Ethoxy-phenyl)-4-p-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

15 (Compound 267) 4-(4-Fluoro-phenyl)-6'-naphthalen-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 268) 6'-(2-Fluoro-biphenyl-4-yl)-4-(4-fluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 269) {4-[4-(4-Fluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-methanol;

20 (Compound 270) 4-(4-Fluoro-phenyl)-6'-furan-3-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 271) 6'-(4-Ethoxy-phenyl)-4-(4-fluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

25 (Compound 272) 6'-Benzo[b]thiophen-2-yl-4-(2,4-difluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 273) 1-{3-[4-(2,4-Difluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-ethanone;

(Compound 274) 4-(2,4-Difluoro-phenyl)-6'-(4-methylsulfanyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

30 (Compound 275) 1-{4-[4-(2,4-Difluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-ethanone;

(Compound 276) 1-{4-[6'-(4-Fluoro-phenyl)-2,3,5,6-tetrahydro-2H-[1,2']bipyrazinyl-4-yl]-phenyl}-ethanone;

35 (Compound 277) 2-Furan-3-yl-6-(4-phenyl-piperidin-1-yl)-pyrazine;

(Compound 278) 2-(3-Fluoro-4-methoxy-phenyl)-6-(4-phenyl-piperidin-1-yl)-pyrazine;

(Compound 279) 6'-Benzo[b]thiophen-3-yl-3-methyl-4-m-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 280) Dimethyl-{4-[6-(4-phenyl-piperidin-1-yl)-pyrazin-2-yl]-phenyl}-amine;

5 (Compound 281) 6'-(3-Chloro-4-fluoro-phenyl)-4-(2,4-dimethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 282) 6'-Benzofuran-2-yl-4-(4-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

10 (Compound 283) 6'-Benzo[b]thiophen-3-yl-4-(4-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 284) 4-(3-Methoxy-phenyl)-6'-p-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 285) 6'-Benzofuran-2-yl-4-(3-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

15 (Compound 286) 6'-Benzo[b]thiophen-3-yl-4-(3-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 287) 4-(3,4-Dichloro-phenyl)-6'-naphthalen-1-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 288) 6'-(3,4-Dimethoxy-phenyl)-4-(2,4-dimethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

20 (Compound 289) 1-{5-[4-(2,4-Dimethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-thiophen-2-yl}-ethanone;

(Compound 290) 4-[4-(4-Methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-benzamide;

25 (Compound 291) 4-(4-Methoxy-phenyl)-6'-phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 292) 6'-Benzo[b]thiophen-2-yl-4-(4-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 293) 4-[4-(4-Methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-benzonitrile;

30 (Compound 294) 4-(4-Methoxy-phenyl)-6'-(3-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 295) 6'-Benzo[b]thiophen-2-yl-4-(2,3-dimethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

35 (Compound 296) 1-{5-[4-(2,3-Dimethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-thiophen-2-yl}-ethanone;

(Compound 297) 1-{3-[4-(2,3-Dimethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-ethanone;

(Compound 298) 1-{4-[4-(2,3-Dimethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-ethanone;

(Compound 299) 4-(3-Methyl-4-m-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-benzamide;

5 (Compound 300) 6'-Benzo[b]thiophen-2-yl-3-methyl-4-m-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 301) 3-Methyl-6'-(4-methylsulfanyl-phenyl)-4-m-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

10 (Compound 302) 4-(4-Chloro-phenyl)-6'-(3-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 303) 4-(4-Pyridin-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-benzonitrile;

(Compound 304) 6'-(3-Methoxy-phenyl)-4-pyridin-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

15 (Compound 305) 6'-(4-Fluoro-phenyl)-4-pyridin-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 306) 6'-(3,4-Dimethoxy-phenyl)-4-pyridin-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 307) 1-[3-(4-Pyridin-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-phenyl]-ethanone;

20 (Compound 308) 1-[4-(4-Pyridin-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-phenyl]-ethanone;

(Compound 309) 6'-(4-Fluoro-phenyl)-4-(4-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

25 (Compound 310) 6'-(3,4-Dimethoxy-phenyl)-4-(4-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 311) 6'-(4-Methylsulfanyl-phenyl)-4-(4-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 312) 1-[3-(2',3',5',6'-Tetrahydro-[2,1';4',2"]terpyrazin-6-yl)-phenyl]-ethanone;

30 (Compound 313) 6-(4-Bromo-phenyl)-2',3',5',6'-tetrahydro-[2,1';4',2"]terpyrazine;

(Compound 314) 6-(4-Methylsulfanyl-phenyl)-2',3',5',6'-tetrahydro-[2,1';4',2"]terpyrazine;

35 (Compound 315) {4-[4-(3,4-Dichloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-methanol;

(Compound 316) 6'-(3-Chloro-4-fluoro-phenyl)-4-(3,4-dimethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 317) 6'-Benzo[b]thiophen-3-yl-4-(3,4-dimethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 318) 2-Naphthalen-1-yl-6-(4-phenyl-piperidin-1-yl)-pyrazine;

(Compound 319) 2-Benzo[b]thiophen-3-yl-6-(4-phenyl-piperidin-1-yl)-pyrazine;

5 (Compound 320) 4-(2,4-Dimethyl-phenyl)-6'-naphthalen-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 321) {4-[4-(2,4-Dimethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-methanol;

10 (Compound 322) 4-(3-Methoxy-phenyl)-6'-naphthalen-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 323) {4-[4-(3-Methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-methanol;

(Compound 324) 6'-Furan-3-yl-4-(3-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

15 (Compound 325) 4-(4-Chloro-phenyl)-6'-m-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 326) 6'-Benzo[b]thiophen-3-yl-4-(4-chloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

20 (Compound 327) 4-Pyridin-2-yl-6'-m-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 328) 4-Pyridin-2-yl-6'-p-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 329) 6-m-Tolyl-2',3',5',6'-tetrahydro-[2,1';4',2"]terpyrazine;

25 (Compound 330) 6-p-Tolyl-2',3',5',6'-tetrahydro-[2,1';4',2"]terpyrazine;

(Compound 331) 6-Naphthalen-1-yl-2',3',5',6'-tetrahydro-[2,1';4',2"]terpyrazine;

(Compound 332) 6-Benzo[b]thiophen-3-yl-2',3',5',6'-tetrahydro-[2,1';4',2"]terpyrazine;

30 (Compound 333) 6-(4-tert-Butyl-phenyl)-2',3',5',6'-tetrahydro-[2,1';4',2"]terpyrazine;

(Compound 334) 6-(2-Fluoro-biphenyl-4-yl)-2',3',5',6'-tetrahydro-[2,1';4',2"]terpyrazine;

(Compound 335) 4-(3,4-Dimethyl-phenyl)-6'-naphthalen-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

35 (Compound 336) 2-(4-Phenyl-piperidin-1-yl)-6-thiophen-3-yl-pyrazine;

(Compound 337) 2-Naphthalen-2-yl-6-(4-phenyl-piperidin-1-yl)-pyrazine;

(Compound 338) 4-(2,3-Dimethyl-phenyl)-6'-(3,5-dimethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 339) 6'-(3,5-Dimethyl-phenyl)-3-methyl-4-m-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

5 (Compound 340) {4-[4-(4-Chloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-dimethyl-amine;

(Compound 341) 6'-(4-Phenoxy-phenyl)-4-pyridin-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

10 (Compound 342) 6'-(2-Methylsulfanyl-phenyl)-4-pyridin-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 343) Dimethyl-[4-(2',3',5',6'-tetrahydro-[2,1';4',2"]terpyrazin-6-yl)-phenyl]-amine;

(Compound 344) 6-(3,5-Dimethyl-phenyl)-2',3',5',6'-tetrahydro-[2,1';4',2"]terpyrazine;

15 (Compound 345) 6-(4-Trifluoromethyl-phenyl)-2',3',5',6'-tetrahydro-[2,1';4',2"]terpyrazine;

(Compound 346) 4-(2,3-Dimethyl-phenyl)-6'-furan-3-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 347) 3-Methyl-6'-naphthalen-2-yl-4-m-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

20 (Compound 348) 4-(4-Chloro-phenyl)-6'-naphthalen-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 349) 4-(4-Chloro-phenyl)-6'-furan-3-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

25 (Compound 350) 4-Pyridin-2-yl-6'-thiophen-3-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 351) [4-(4-Pyridin-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl)-phenyl]-methanol;

(Compound 352) 6'-Naphthalen-2-yl-4-(4-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

30 (Compound 353) 6'-Furan-3-yl-4-(4-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 354) 4-(2,4-Dimethyl-phenyl)-6'-(4-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

35 (Compound 355) 4-(4-Methoxy-phenyl)-6'-(4-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 356) 4-(3-Methoxy-phenyl)-6'-(4-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 357) {4-[4-(3,4-Dichloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-dimethyl-amine;

(Compound 358) 4-(3,4-Dichloro-phenyl)-6'-(3,5-dimethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

5 (Compound 359) 4-(3,4-Dimethyl-phenyl)-6'-(4-methylsulfanyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 360) 2-(3,4-Dimethoxy-phenyl)-6-(4-phenyl-piperidin-1-yl)-pyrazine;

10 (Compound 361) 2-(4-Methylsulfanyl-phenyl)-6-(4-phenyl-piperidin-1-yl)-pyrazine;

(Compound 362) 1-{4-[6-(4-Phenyl-piperidin-1-yl)-pyrazin-2-yl]-phenyl}-ethanone;

(Compound 363) 6'-(4-Fluoro-phenyl)-4-(4-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

15 (Compound 364) 4-[4-(3-Methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-benzamide;

(Compound 365) 4-(3-Methoxy-phenyl)-6'-phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 366) 4,6'-Bis-(3-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

20 (Compound 367) 6'-(4-Fluoro-phenyl)-4-(3-methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 368) 1-{3-[4-(3-Methoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-6'-yl]-phenyl}-ethanone;

25 (Compound 369) 4-(3-Methoxy-phenyl)-6'-(4-methylsulfanyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 370) 4-(3,4-Dichloro-phenyl)-6'-(4-fluoro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 371) 4-(3,4-Dichloro-phenyl)-6'-(3,4-dimethoxy-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

30 (Compound 372) 4-(3,4-Dichloro-phenyl)-6'-(4-methylsulfanyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

(Compound 373) 6'-Benzo[b]thiophen-2-yl-3',5'-dimethyl-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl;

35 (Compound 374) [6-(3-Amino-phenyl)-pyrazin-2-yl]-(3,4,5-trimethoxy-phenyl)-amine;

(Compound 375) N-{3-[6-(3,4,5-Trimethoxy-phenylamino)-pyrazin-2-yl]-phenyl}-acetamide;

(Compound 376) [6-(4-Isopropyl-phenyl)-pyrazin-2-yl]-(3,4,5-trimethoxy-phenyl)-amine;

(Compound 377) [6-(4-Methoxy-phenyl)-pyrazin-2-yl]-(2,2,3,3-tetrafluoro-2,3-dihydro-benzo[1,4]dioxin-6-yl)-amine;

5 (Compound 378) 3-[6-(2,2,3,3-Tetrafluoro-2,3-dihydro-benzo[1,4]dioxin-6-ylamino)-pyrazin-2-yl]-phenol;

(Compound 379) [6-(3-Amino-phenyl)-pyrazin-2-yl]-(3-chloro-phenyl)-amine;

10 (Compound 380) [6-(3-Amino-phenyl)-pyrazin-2-yl]-(4-chloro-phenyl)-amine;

(Compound 381) 3-[6-(4-Chloro-phenylamino)-pyrazin-2-yl]-N-(2-dimethylamino-ethyl)-benzamide;

(Compound 382) (3-Chloro-4-fluoro-phenyl)-[6-(3,4,5-trimethoxy-phenyl)-pyrazin-2-yl]-amine;

15 (Compound 383) 3-[6-(3-Chloro-4-fluoro-phenylamino)-pyrazin-2-yl]-N-(2-dimethylamino-ethyl)-benzamide;

(Compound 384) [6-(4-Methoxy-phenyl)-pyrazin-2-yl]-(3-trifluoromethyl-phenyl)-amine;

(Compound 385) (3-Chloro-phenyl)-[6-(3-chloro-phenyl)-pyrazin-2-yl]-amine;

20 (Compound 386) 4-(6-Phenylamino-pyrazin-2-yl)-phenol;

(Compound 387) N-{3-[6-(4-Chloro-phenylamino)-pyrazin-2-yl]-phenyl}-acetamide;

(Compound 388) 3-[6-(4-Methoxy-phenyl)-pyrazin-2-ylamino]-benzonitrile;

25 (Compound 389) 3-[6-(4-Amino-phenyl)-pyrazin-2-ylamino]-benzonitrile;

(Compound 390) [6-(3-Dimethylamino-phenyl)-pyrazin-2-yl]-(3,4,5-trimethoxy-phenyl)-amine;

(Compound 391) 3-[6-(3-Dimethylamino-phenyl)-pyrazin-2-ylamino]-benzonitrile;

30 (Compound 392) [6-(4-Ethoxy-phenyl)-pyrazin-2-yl]-(3,4,5-trimethoxy-phenyl)-amine;

(Compound 393) [6-(4-Amino-phenyl)-pyrazin-2-yl]-(3-trifluoromethyl-phenyl)-amine;

35 (Compound 394) (4-Chloro-phenyl)-[6-(3-dimethylamino-phenyl)-pyrazin-2-yl]-amine;

(Compound 395) [6-(3-Dimethylamino-phenyl)-pyrazin-2-yl]-phenyl-amine;

(Compound 396) 4-[6-(3,4,5-Trimethoxy-phenylamino)-pyrazin-2-yl]-phenol;

(Compound 397) N-{4-[6-(4-Chloro-phenylamino)-pyrazin-2-yl]-phenyl}-acetamide;

5 (Compound 398) [6-(4-Amino-phenyl)-pyrazin-2-yl]-(3,4,5-trimethoxy-phenyl)-amine;

(Compound 399) N-{4-[6-(3-Chloro-4-fluoro-phenylamino)-pyrazin-2-yl]-phenyl}-acetamide;

10 (Compound 400) [3-(6-Phenylamino-pyrazin-2-yl)-phenyl]-methanol;

(Compound 401) N-[4-(6-Phenylamino-pyrazin-2-yl)-phenyl]-acetamide;

(Compound 402) (6-Naphthalen-2-yl-pyrazin-2-yl)-(3,4,5-trimethoxy-phenyl)-amine;

15 (Compound 403) N-{3-[6-(2,2,3,3-Tetrafluoro-2,3-dihydro-benzo[1,4]dioxin-6-ylamino)-pyrazin-2-yl]-phenyl}-acetamide;

(Compound 404) 3-[6-(3-Chloro-phenylamino)-pyrazin-2-yl]-N-(2-dimethylamino-ethyl)-benzamide;

(Compound 405) N-{3-[6-(3-Chloro-4-fluoro-phenylamino)-pyrazin-2-yl]-phenyl}-acetamide;

(Compound 406) 4-(6-Phenylamino-pyrazin-2-yl)-benzamide;

20 (Compound 407) [6-(2,4-Difluoro-phenyl)-pyrazin-2-yl]-(3,4,5-trimethoxy-phenyl)-amine;

(Compound 408) [6-(4-Amino-phenyl)-pyrazin-2-yl]-(3-chloro-phenyl)-amine;

(Compound 409) N-{5-[6-(3-Dimethylamino-phenyl)-pyrazin-2-ylamino]-2-methyl-phenyl}-methanesulfonamide;

25 (Compound 410) N-{5-[6-(2,4-Difluoro-phenyl)-pyrazin-2-ylamino]-2-methyl-phenyl}-methanesulfonamide;

(Compound 411) [6-(4-Ethoxy-phenyl)-pyrazin-2-yl]-(3-trifluoromethyl-phenyl)-amine;

30 (Compound 412) 4-[6-(3-Chloro-phenylamino)-pyrazin-2-yl]-benzamide;

(Compound 413) 4-[6-(4-Amino-phenyl)-pyrazin-2-ylamino]-benzonitrile;

(Compound 414) 4-[6-(3,4,5-Trimethoxy-phenylamino)-pyrazin-2-yl]-benzamide;

35 (Compound 415) N-{3-[6-(3-Chloro-phenylamino)-pyrazin-2-yl]-phenyl}-acetamide;

(Compound 416) N-[3-(6-Phenylamino-pyrazin-2-yl)-phenyl]-acetamide;

(Compound 417) 3-[6-(3-Chloro-4-fluoro-phenylamino)-pyrazin-2-yl]-phenol;

(Compound 418) N-[3-[6-(3-Trifluoromethyl-phenylamino)-pyrazin-2-yl]-phenyl]-acetamide;

(Compound 419) (4-Chloro-phenyl)-[6-(3,4,5-trimethoxy-phenyl)-pyrazin-2-yl]-amine;

5 (Compound 420) {2-[6-(4-Chloro-phenylamino)-pyrazin-2-yl]-phenyl}-methanol;

(Compound 421) 3-[6-(3-Amino-phenyl)-pyrazin-2-ylamino]-benzonitrile;

(Compound 422) 3-[6-(5-Isopropyl-2-methoxy-phenyl)-pyrazin-2-ylamino]-benzonitrile;

10 (Compound 423) 3-[6-(3,4,5-Trimethoxy-phenylamino)-pyrazin-2-yl]-phenol;

(Compound 424) N-[2-Methyl-5-(6-naphthalen-2-yl-pyrazin-2-ylamino)-phenyl]-methanesulfonamide;

(Compound 425) 5-(3-Amino-phenyl)-N*3*-(4-methoxy-phenyl)-pyrazine-2,3-diamine;

15 (Compound 426) N*3*-(1H-Indol-5-yl)-5-(4-morpholin-4-yl-phenyl)-pyrazine-2,3-diamine;

(Compound 427) 5-(3-Amino-phenyl)-N*3*-(1H-indol-5-yl)-pyrazine-2,3-diamine;

20 (Compound 428) 4-[5-Amino-6-(1H-indol-5-ylamino)-pyrazin-2-yl]-phenol;

(Compound 429) 5-(3-Dimethylamino-phenyl)-N*3*-(1H-indol-5-yl)-pyrazine-2,3-diamine;

(Compound 430) N*3*-(1H-Indol-5-yl)-5-(4-methanesulfonyl-phenyl)-pyrazine-2,3-diamine;

25 (Compound 431) N*3*-(1H-Indol-5-yl)-5-(5-isopropyl-2-methoxy-phenyl)-pyrazine-2,3-diamine;

(Compound 432) N*3*-(1H-Indol-5-yl)-5-(3-methoxy-phenyl)-pyrazine-2,3-diamine;

(Compound 433) N*3*-(1H-Indol-5-yl)-5-quinolin-5-yl-pyrazine-2,3-diamine;

30 (Compound 434) 3-[5-Amino-6-(4-methoxy-phenylamino)-pyrazin-2-yl]-benzoic acid;

(Compound 435) 5-(4-Methanesulfonyl-phenyl)-N*3*-(4-methoxy-phenyl)-pyrazine-2,3-diamine;

35 (Compound 436) (E)-3-{3-[5-Amino-6-(4-methoxy-phenylamino)-pyrazin-2-yl]-phenyl}-acrylic acid;

(Compound 437) 5-(3-Bromo-phenyl)-N*3*-(4-methoxy-phenyl)-pyrazine-2,3-diamine;

(Compound 438) 5-(5-Isopropyl-2-methoxy-phenyl)-N³*-(4-methoxy-2-methyl-phenyl)-pyrazine-2,3-diamine;

(Compound 439) {3-[5-Amino-6-(4-methoxy-2-methyl-phenylamino)-pyrazin-2-yl]-phenyl}-methanol;

5 (Compound 440) 3-[5-Amino-6-(4-methoxy-2-methyl-phenylamino)-pyrazin-2-yl]-benzamide;

(Compound 441) [6-(3-Amino-phenyl)-pyrazin-2-yl]-(3,4,5-trimethoxy-phenyl)-amine.

10 28. A compound according to any one of claims 1 to 27 for use as a pharmaceutically active agent.

29. Use of a compound according to any one of claims 1 – 28 as an inhibitor for a protein kinase.

15 30. Use of at least one compound according to one of claims 1 – 28 for the preparation of a pharmaceutical composition for the prophylaxis and / or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke.

20 31. Use according to claim 30, wherein the virally induced infectious diseases, including opportunistic diseases, are caused by retroviruses, human endogenous retroviruses, lentiviruses, oncoretroviruses, hepadnaviruses, herpesviruses, flaviviridae, and/or adenoviruses.

25 32. Use according to claim 30 or 31, wherein the infective disease including opportunistic infection is selected from the group comprising AIDS, Alveolar Hydatid Disease (AHD, Echinococcosis), Amebiasis (*Entamoeba histolytica* Infection), *Angiostrongylus* Infection, *Anisakiasis*, *Anthrax*, *Babesiosis* (*Babesia* Infection), *Balantidium* Infection (*Balantidiasis*), *Baylisascaris* Infection (Raccoon Roundworm), *Bilharzia* (*Schistosomiasis*), *Blastocystis* Infection (*Blastomycosis*), *Boreliosis*, *Botulism*, *Brainerd* 30 *hominis* Infection (*Blastomycosis*), *Diarrhea*, *Brucellosis*, *BSE* (Bovine Spongiform Encephalopathy), *Candidiasis*, *Capillariasis* (*Capillaria* Infection), *CFS* (Chronic Fatigue Syndrome), *Chagas Disease* (American Trypanosomiasis), *Chickenpox* (*Varicella-Zoster* virus), *Chlamydia pneumoniae* Infection, *Cholera*, *Chronic Fatigue Syndrome*, *CJD* (Creutzfeldt-Jakob Disease),

35 40

Clonorchiasis (Clonorchis Infection), CLM (Cutaneous Larva Migrans, Hookworm Infection), Coccidioidomycosis, Conjunctivitis, Coxsackievirus A16 (Hand, Foot and Mouth Disease), Cryptococcosis, Cryptosporidium Infection (Cryptosporidiosis), Culex mosquito (Vector of West Nile Virus),
5 Cutaneous Larva Migrans (CLM), Cyclosporiasis (Cyclospora Infection), Cysticercosis (Neurocysticercosis), Cytomegalovirus Infection, Dengue / Dengue Fever, Ebola Virus Hemorrhagic Fever, Echinococcosis (Alveolar Hydatid Disease), Encephalitis, Entamoeba coli Infection, Entamoeba dispar Infection, Entamoeba hartmanni Infection, Entamoeba histolytica Infection (Amebiasis), Entamoeba polecki Infection, Enterobiasis (Pinworm Infection), Enterovirus Infection (Non-Polio), Epstein-Barr Virus Infection, Escherichia coli Infection, Foodborne Infection, Foot and mouth Disease, Fungal Dermatitis, Gastroenteritis, Group A streptococcal Disease, Group 10 B streptococcal Disease, Hansen's Disease (Leprosy), Hantavirus Pulmonary Syndrome, Helicobacter pylori Infection, Hematologic Disease, Hendra Virus Infection, Hepatitis (HCV, HBV), Herpes Zoster (Shingles), HIV Infection, Human Ehrlichiosis, Human Parainfluenza Virus Infection, Influenza, Isosporiasis (Isospora Infection), Lassa Fever, Leishmaniasis, Kala-azar (Kala-azar, Leishmania Infection), Leprosy, Lice (Body lice, Head lice, Pubic lice), Lyme Disease, Malaria, Marburg Hemorrhagic Fever, Measles, Meningitis, Mosquito-borne Diseases, Mycobacterium avium Complex (MAC) Infection, Naegleria Infection, Nosocomial Infections, Nonpathogenic Intestinal Amebae Infection, Onchocerciasis (River Blindness), Opisthorciasis (Opisthorcis Infection), Parvovirus Infection, Plague, PCP (Pneumocystis carinii Pneumonia), Polio, Q Fever, Rabies, Respiratory Syncytial Virus (RSV) Infection, Rheumatic Fever, Rift Valley Fever, River Blindness (Onchocerciasis), Rotavirus Infection, Roundworms Infection, Salmonellosis, Salmonella Enteritidis, Scabies, Shigellosis, Shingles, Sleeping Sickness, Smallpox, Streptococcal Infection, Tapeworm Infection (Taenia Infection), Tetanus, Toxic Shock Syndrome, Tuberculosis, Ulcers (Peptic Ulcer Disease), Valley Fever, Vibrio parahaemolyticus Infection, Vibrio vulnificus Infection, Viral Hemorrhagic Fever, Warts, Waterborne infectious Diseases, West Nile Virus Infection (West Nile Encephalitis), Whooping Cough, Yellow 20 Fever, tuberculosis, leprosy, mycobacteria-induced meningitis.

30 33. Use according to claim 30, wherein the prion diseases is selected from the group comprising Scrapie, TME, CWD, BSE, CJD, vCJD, GSS, FFI, Kuru, and Alpers Syndrome.

35

34. Use according to claim 30, wherein the immunological disease and/or autoimmune disease is selected from the group comprising:
5 asthma, diabetes, rheumatic diseases, AIDS, rejection of transplanted organs and tissues, rhinitis, chronic obstructive pulmonary diseases, osteoporosis, ulcerative colitis, sinusitis, lupus erythematosus, recurrent infections, atopic dermatitis / eczema and occupational allergies, food allergies, drug allergies, severe anaphylactic reactions, anaphylaxis, manifestations of allergic diseases, primary immunodeficiencies, antibody deficiency states, cell mediated immunodeficiencies, severe combined immunodeficiency, DiGeorge syndrome, Hyper-IgE syndrome, Wiskott-Aldrich syndrome, ataxia-telangiectasia, immune mediated cancers, white cell defects, autoimmune diseases, systemic lupus erythematosus, rheumatoid arthritis (RA), multiple sclerosis (MS), immune-mediated or
10 Type 1 Diabetes Mellitus, immune mediated glomerulonephritis, scleroderma, pernicious anemia, alopecia, pemphigus, pemphigus vulgaris, myasthenia gravis, inflammatory bowel diseases, Crohn's disease, psoriasis, autoimmune thyroid diseases, Hashimoto's disease, dermatomyositis, goodpasture syndrome, myasthenia gravis
15 pseudoparalytica, ophtalmia sympathica, phakogene uveitis, chronical agressivce hepatitis, primary billiary cirrhosis, autoimunehemolytic anemy, Werlof disease.

35. Use according to claim 30, wherein the bipolar and/or clinical disorder is
25 selected from the group comprising: adjustment disorders, anxiety disorders, delirium, dementia, amnestic and other cognitive disorders, disorders usually first diagnosed in infancy, childhood, or adolescence, dissociative disorders, eating disorders, factitious disorders, impulse-control disorders, mental disorders due to a general medical condition, mood disorders, other
30 conditions that may be a focus of clinical attention, personality disorders, schizophrenia and other psychotic disorders, sleep disorders, somatoform disorders, substance-related disorders, generalized anxiety disorder, panic disorder, phobia, agoraphobia, obsessive-compulsive disorder, stress, acute stress disorder, anxiety neurosis, nervousness, phobia, posttraumatic stress disorder, posttraumatic stress disorder (PTSD), abuse, ADHD, obsessive-compulsive disorder (OCD), manic depressive psychosis, specific phobias, social phobia, adjustment disorder with anxious features.

35

36. Use according to claim 35, wherein the anxiety disorders, delirium, dementia, amnestic and other cognitive disorders, disorders usually first diagnosed in infancy, childhood, or adolescence, dissociative disorders, eating disorders, mood disorders, schizophrenia and other psychotic disorders, sexual and gender identity disorders, sleep disorders, somatoform disorders, substance-related disorders are selected from the group comprising: acute stress disorder, agoraphobia without history of panic disorder, anxiety disorder due to general medical condition, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder with agoraphobia, panic disorder without agoraphobia, posttraumatic stress disorder, specific phobia, social phobia, substance-induced anxiety disorder, delirium due to a general medical condition, substance intoxication delirium, substance withdrawal delirium, delirium due to multiple etiologies, Alzheimer's, Creutzfeldt-Jakob disease, head trauma, Huntington's disease, HIV disease, Parkinson's disease, Pick's disease, substance-induced persisting, vascular, dementia due to other general medical conditions, dementia due to multiple etiologies, amnestic disorder due to a general medical condition, substance-induced persisting amnestic disorder, mental retardation, learning disorders, mathematics disorder, reading disorder, disorder of written expression, learning disorder, motor skills disorders, developmental coordination disorder, communication disorders, phonological disorder, pervasive developmental disorders, Asperger's disorder, autistic disorder, childhood disintegrative disorder, Rett's disorder, pervasive developmental disorder, attention-deficit/hyperactivity disorder (ADHD), conduct disorder, oppositional defiant disorder, feeding disorder of infancy or early childhood, pica, rumination disorder, tic disorders, chronic motor or vocal tic disorder, Tourette's disorder, elimination disorders, encopresis, enuresis, selective mutism, separation anxiety disorder, reactive attachment disorder of infancy or early childhood, stereotypic movement disorder, dissociative amnesia, depersonalization disorder, dissociative fugue, dissociative identity disorder, anorexia nervosa, bulimia nervosa, mood episodes, major depressive episode, hypomanic episode, manic episode, mixed episode, depressive disorders, dysthymic disorder, major depressive disorder, single episode, recurrent, bipolar disorders, bipolar I disorder, bipolar II disorder, cyclothymic disorder, mood disorder due to a general medical condition, substance-induced mood disorder, schizopreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, delusions, hallucinations, substance-induced psychotic disorder, female

5 sexual arousal disorder, orgasmic disorders, premature ejaculation, sexual pain disorders, dyspareunia, vaginismus, sexual dysfunction due to a general medical condition, female dyspareunia, female hypoactive sexual desire disorder, male erectile disorder, male hypoactive sexual desire disorder, male dyspareunia, other female sexual dysfunction, other male sexual dysfunction, substance-induced sexual dysfunction, sexual dysfunction, paraphilias, dyssomnias, breathing-related sleep disorder, circadian rhythm sleep disorder, hypersomnia, hypersomnia related to another mental disorder, insomnia, insomnia related to another mental disorder, narcolepsy, 10 dyssomnia, parasomnias, nightmare disorder, sleep terror disorder, sleepwalking disorder, parasomnia, body dysmorphic disorder, conversion disorder, hypochondriasis, pain disorder, somatization disorder, undifferentiated somatoform disorder, alcohol related disorders, amphetamine related disorders, caffeine related disorders, cannabis related disorders, 15 cocaine related disorders, hallucinogen related disorders, inhalant related disorders, nicotine related disorders, opioid related disorders, psychotic disorder, psychotic disorder, phencyclidine-related disorder, abuse, persisting amnestic disorder, anxiety disorder, persisting dementia, dependence, intoxication, intoxication delirium, mood disorder, psychotic disorder, 20 withdrawal, withdrawal delirium, sexual dysfunction, sleep disorder.

37. Use according to claim 30, wherein the cardiovascular diseases are selected from the group consisting of:

25 adult congenital heart disease, aneurysm, stable angina, unstable angina, angina pectoris, angioneurotic edema, aortic valve stenosis, aortic aneurysm, arrhythmia, arrhythmogenic right ventricular dysplasia, arteriosclerosis, arteriovenous malformations, atrial fibrillation, Behcet syndrome, bradycardia, 30 cardiac tamponade, cardiomegaly, congestive cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, cardiovascular disease prevention, carotid stenosis, cerebral hemorrhage, Churg-Strauss syndrome, diabetes, Ebstein's Anomaly, Eisenmenger complex, cholesterol embolism, bacterial endocarditis, fibromuscular dysplasia, congenital heart defects, heart diseases, congestive heart failure, heart valve diseases, heart attack, epidural hematoma, hematoma, subdural, Hippel-Lindau disease, hyperemia, 35 hypertension, pulmonary hypertension, hypertrophic growth, left ventricular hypertrophy, right ventricular hypertrophy, hypoplastic left heart syndrome, hypotension, intermittent claudication, ischemic heart disease, Klippel-Trenaunay-Weber syndrome, lateral medullary syndrome, long QT syndrome mitral valve prolapse, moyamoya disease, mucocutaneous lymph node

syndrome, myocardial infarction, myocardial ischemia, myocarditis, pericarditis, peripheral vascular diseases, phlebitis, polyarteritis nodosa, pulmonary atresia, Raynaud disease, restenosis, Sneddon syndrome, stenosis, superior vena cava syndrome, syndrome X, tachycardia, Takayasu's arteritis, hereditary hemorrhagic telangiectasia, telangiectasis, temporal arteritis, tetralogy of fallot, thromboangiitis obliterans, thrombosis, thromboembolism, tricuspid atresia, varicose veins, vascular diseases, vasculitis, vasospasm, ventricular fibrillation, Williams syndrome, peripheral vascular disease, varicose veins and leg ulcers, deep vein thrombosis, Wolff-Parkinson-White syndrome.

38. Use according to claim 30, wherein the proliferative disease is selected from the group comprising: adenocarcinoma, choroidal melanoma, acute leukemia, acoustic neurinoma, ampullary carcinoma, anal carcinoma, astrocytoma, basal cell carcinoma, pancreatic cancer, desmoid tumor, bladder cancer, bronchial carcinoma, breast cancer, Burkitt's lymphoma, corpus cancer, CUP-syndrome (carcinoma of unknown primary), colorectal cancer, small intestine cancer, small intestinal tumors, ovarian cancer, endometrial carcinoma, ependymoma, epithelial cancer types, Ewing's tumors, gastrointestinal tumors, gastric cancer, gallbladder cancer, gall bladder carcinomas, uterine cancer, cervical cancer, cervix, glioblastomas, gynecologic tumors, ear, nose and throat tumors, hematologic neoplasias, hairy cell leukemia, urethral cancer, skin cancer, skin testis cancer, brain tumors (gliomas), brain metastases, testicle cancer, hypophysis tumor, carcinoids, Kaposi's sarcoma, laryngeal cancer, germ cell tumor, bone cancer, colorectal carcinoma, head and neck tumors (tumors of the ear, nose and throat area), colon carcinoma, craniopharyngiomas, oral cancer (cancer in the mouth area and on lips), cancer of the central nervous system, liver cancer, liver metastases, leukemia, eyelid tumor, lung cancer, lymph node cancer (Hodgkin's/Non-Hodgkin's), lymphomas, stomach cancer, malignant melanoma, malignant neoplasia, malignant tumors gastrointestinal tract, breast carcinoma, rectal cancer, medulloblastomas, melanoma, meningiomas, Hodgkin's disease, mycosis fungoides, nasal cancer, neurinoma, neuroblastoma, kidney cancer, renal cell carcinomas, non-Hodgkin's lymphomas, oligodendrogloma, esophageal carcinoma, osteolytic carcinomas and osteoplastic carcinomas, osteosarcomas, ovarian carcinoma, pancreatic carcinoma, penile cancer, plasmacytoma, prostate cancer, pharyngeal cancer, rectal carcinoma, retinoblastoma, vaginal

5 cancer, thyroid carcinoma, Schneeberger disease, esophageal cancer, spinalioms, T-cell lymphoma (mycosis fungoides), thymoma, tube carcinoma, eye tumors, urethral cancer, urologic tumors, urothelial carcinoma, vulva cancer, wart appearance, soft tissue tumors, soft tissue sarcoma, Wilm's tumor, cervical carcinoma and tongue cancer.

10 39. Use according to claim 30, wherein said diabetes is selected from Type I diabetes or Type II diabetes.

15 40. Use according to claim 30, wherein said inflammation is mediated by the cytokines TNF- α , IL-1 β , GM-CSF, IL-6 and/or IL-8.

15 41. Use according to claim 30 or 40 wherein the inflammatory disease is caused, induced, initiated and/or enhanced by bacteria, viruses, prions, parasites, fungi, and/or caused by irritative, traumatic, metabolic, allergic, autoimmune, or idiopathic reasons.

20 42. Use according to claim 41 wherein the viruses and bacteria are selected from the group comprising human immunodeficiency virus-I, herpes viruses, herpes simplex virus, herpes zoster virus, cytomegalovirus, mycoplasma pulmonis, ureaplasma urealyticum, mycoplasma pneumoniae, chlamydia pneumoniae, C. pneumoniae, Helicobacter pylori, and propiono-bacterium.

25 43. Use according to any one of the claims 30, 40 – 42, wherein the inflammatory disease is selected from the group comprising inflammatory diseases of the central nervous system (CNS), inflammatory rheumatic diseases, inflammatory diseases of blood vessels, inflammatory diseases of the middle ear, inflammatory bowel diseases, inflammatory diseases of the skin, inflammatory disease uveitis, inflammatory diseases of the larynx.

30 44. Use according to claim 43 wherein the inflammatory diseases of the central nervous system (CNS), inflammatory rheumatic diseases, inflammatory diseases of blood vessels, inflammatory diseases of the middle ear, inflammatory bowel diseases, inflammatory diseases of the skin, inflammatory disease uveitis, inflammatory diseases of the larynx are selected from the group comprising:
abscessation, acanthameba, acanthamebiasis, acne vulgaris, actinomycosis, acute inflammatory dermatoses, acute laryngeal infections of adults, acute multifocal placoid pigmentary epitheliopathy, acute

35

40

(thermal) injury, acute retinal necrosis, acute suppurative otitis media, algal disorders, allergic contact dermatitis, amyloidosis angioedema, ankylosing spondylitis, aspergillosis, atopic dermatitis, Aujeszky's disease, autoantibodies in vasculitis, babesiosis, bacterial disorders, 5 bacterial laryngitis, bacterial meningitis, Behcet's disease, birdshot choroidopathy, blastomycosis, borna disease, brucellosis, bullous myringitis, bursitis, candidiasis, canine distemper encephalomyelitis, canine distemper encephalomyelitis in immature animals, canine ehrlichiosis, cholesteatoma, chronic (granulomatous) diseases, chronic 10 inflammatory dermatoses, chronic relapsing encephalomyelitis, chronic suppurative otitis media, cicatricial pemphigoid, coccidiomycosis, coccidioidomycosis, common upper respiratory infection, contact ulcer and granuloma, Crohn's disease, cryptococcosis, cysticercosis, dermatomyositis, diphtheria, discoid lupus erythematosus, drug-induced 15 vasculitis, drug or hypersensitivity reaction, encephalitozoonosis, eosinophilic meningoencephalitis, erythema multiforme (EM minor), feline leukemia virus, feline immunodeficiency virus, feline infectious peritonitis, feline polioencephalomyelitis, feline spongiform encephalopathy, fibromyositis, Fuch's heterochromic cyclitis, gastroesophageal 20 (laryngopharyngeal) reflux disease, giant cell arteritis, glanders, glaucomatocyclitic crisis, gonorrhea granular myringitis, granulomatous meningoencephalomyelitis, herpes simplex, histoplasmosis, idiopathic diseases, idiopathic inflammatory disorders, immune and idiopathic disorders, infections of the immunocompromised host, infectious canine 25 hepatitis, inhalation laryngitis, interstitial nephritis, irritant contact dermatitis, juvenile rheumatoid arthritis, Kawasaki's disease, La Crosse virus encephalitis, laryngeal abscess, laryngotracheitis (croup), leishmaniasis, lens-induced uveitis, leprosy, leptospirosis, leukemia, lichen planus, lupus, lyme disease, lymphoma, meningitis, 30 meningoencephalitis in greyhounds, miscellaneous meningitis / meningoencephalitis, microscopic polyangiitis, multifocal choroiditis, multiple sclerosis, muscle tension dysphonias, mycotic (fungal) diseases, mycotic diseases of the CNS, necrotizing encephalitis, neosporosis, old dog encephalitis, onchocerciasis, parasitic encephalomyelitis, parasitic 35 infections, pars planitis, parvovirus encephalitis, pediatric laryngitis, pollution and inhalant allergy, polymyositis, post-vaccinal canine distemper encephalitis, post-vaccinal rabies, prion protein induced diseases, protozoal encephalitis-encephalomyelitis, psoriasis,

psoriatic arthritis, pyogranulomatous meningoencephalomyelitis, rabies, radiation injury, radiation laryngitis, radionecrosis, relapsing polychondritis, Reiters's syndrome, retinitis pigmentosa, retinoblastoma, rheumatoid arthritis, rickettsial disorders, rocky mountain spotted fever, salmon poisoning, sarcocystosis, sarcoidosis, schistosomiasis, scleroderma, scleroma, serpiginous choroiditis, shaker dog disease, Sjogren's syndrome, spasmodic croup, spirochetal (syphilis) diseases, spongiotic dermatitis, sporotrichosis, steroid responsive meningitis-arteritis, Stevens-Johnson syndrome (SJS, EM major), supraglottitis (epiglottitis), sympathetic ophthalmia, syngamus laryngeus, syphilis, systemic lupus erythematosus, systemic vasculitis in sarcoidosis, Takayasu's arteritis, tendinitis (tendonitis), thromboangiitis obliterans (Buerger's Disease), toxic epidermal necrolysis (TEN), toxocariasis, toxoplasmosis, trauma, traumatic laryngitis, trichinosis, trypanosomiasis, tuberculosis, tularemia, ulcerative colitis, urticaria (hives), vasculitis, vasculitis and malignancy, vasculitis and rheumatoid arthritis, vasculitis in systemic lupus erythematosus, vasculitis in the idiopathic inflammatory myopathies, vasculitis of the central nervous system, vasculitis secondary to bacterial, fungal, and parasitic infection, viral disorders, viral laryngitis, vitiligo, vocal abuse, vocal-cord hemorrhage, Vogt Koyanagi Harada syndrome, Wegener's granulomatosis, and Whipple's disease.

45. Use according to claim 30, wherein the transplant rejection is selected from the group comprising heart transplant rejection, heart-lung transplant rejection, lung transplant rejection, liver transplant rejection, kidney transplant rejection, pancreas transplant rejection, spleen transplant rejection, skin transplant rejection, tissue transplant rejection, bone marrow transplant rejection, spinal marrow transplant rejection, hormone producing glands transplant rejection, gonads and gonadal gland transplant rejection, graft-versus-host-diseases and host-versus-graft-diseases.

25 46. Use according to claim 30, wherein the neurodegenerative diseases are selected from the group comprising:

30 Alzheimer disease, Parkinson disease, Huntington disease, amyotrophic lateral sclerosis, AIDS-related dementia, retinitis pigmentosa, spinal muscular atrophy and cerebellar degeneration, fragile X-associated tremor/ataxia syndrome (FXTAS), progressive supranuclear palsy (PSP), and striatonigral degeneration (SND), which is included with

35

olivopontocerebellar degeneration (OPCD), and Shy Drager syndrome (SDS) in a syndrome known as multiple system atrophy (MSA).

47. Use according to claim 31, wherein the herpes virus is selected from the group comprising:
5 Herpes simplex viruses, varicello viruses, cytomegalo viruses, muromegalo viruses, roseolo viruses, lymphocrypto viruses and rhadino viruses.

48. Use according to claim 47, wherein the herpes virus is cytomegalovirus, preferably human cytomegalovirus (HCMV).
10

49. Use according to any one of claims 30 – 32, wherein said infectious disease is herpes.
15

50. Use according to claim 29, wherein the protein kinase is UL 97.

51. Use according to any one of claims 28 – 50, wherein at least one compound according to any one of claims 1 – 28 is used in combination with further therapeutic compounds, preferably selected from the group consisting of ganciclovir, foscarnet, cidofovir, valganciclovir, ganciclovir implants, 20 fomivirsen, penciclovir and valaciclovir.

52. Pharmaceutical composition comprising at least one compound according to any one of claims 1 to 28 as an active ingredient, together with at least one pharmaceutically acceptable carrier, excipient and/or diluent.
25

53. Pharmaceutical composition according to claim 52 further comprising an additional therapeutic compound, preferably selected from the group consisting of ganciclovir, foscarnet, cidofovir, valganciclovir, ganciclovir implants, fomivirsen, penciclovir and valaciclovir.
30